Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MeRmaiD-1 adjuvant durvalumab plus platinum chemotherapy in resected MRD-assessed NSCLC
MOH_2020-06-23_009065Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab arm with Placebo arm (2 arms). Planned start Jun 2020; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2020-06-23_009065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-23_009065.